Trial Profile

Phase I/II Trial of Encorafenib, Cetuximab, and Nivolumab in Microsatellite Stable BRAFV600E Metastatic Colorectal Cancer (BMS-MDACC CA209-8P6/ARRAY IST-818-101X)

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 06 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cetuximab (Primary) ; Encorafenib (Primary) ; Nivolumab (Primary)
Indications Adenocarcinoma; Colorectal cancer
Focus Adverse reactions; Therapeutic Use
Acronyms BMS-MDACC CA209-8P6/ARRAY IST-818-101X

Most Recent Events

23 Jul 2025 Planned End Date changed from 30 Jun 2025 to 30 Dec 2025.
23 Jul 2025 Planned primary completion date changed from 30 Jun 2025 to 30 Dec 2025.
18 Jul 2022 Planned primary completion date changed from 30 Jun 2024 to 30 Jun 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com